RSV Prevention in All Infants: Which Is the Most Preferable Strategy?
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Respiratory syncytial virus (RSV) causes a spectrum of respiratory illnesses in infants and young children that may lead to hospitalizations and a substantial number of outpatient visits, which result in a huge economic and healthcare burden. Most hospitalizations happen in otherwise healthy infants, highlighting the need to protect all infants against RSV. Moreover, there is evidence on the association between early-life RSV respiratory illness and recurrent wheezing/asthma-like symptoms As such, RSV is considered a global health priority. However, despite this, the only prevention strategy currently available is palivizumab, a monoclonal antibody (mAb) indicated in a subset of preterm infants or those with comorbidities, hence leaving the majority of the infant population unprotected against this virus. Therefore, development of prevention strategies against RSV for all infants entering their first RSV season constitutes a large unmet medical need. The aim of this review is to explore different immunization approaches to protect all infants against RSV. Prevention strategies include maternal immunization, immunization of infants with vaccines, immunization of infants with licensed mAbs (palivizumab), and immunization of infants with long-acting mAbs (e.g., nirsevimab, MK-1654). Of these, palivizumab use is restricted to a small population of infants and does not offer a solution for all-infant protection, whereas vaccine development in infants has encountered various challenges, including the immaturity of the infant immune system, highlighting that future pediatric vaccines will most likely be used in older infants (>6 months of age) and children. Consequently, maternal immunization and immunization of infants with long-acting mAbs represent the two feasible strategies for protection of all infants against RSV. Here, we present considerations regarding these two strategies covering key areas which include mechanism of action, “consistency” of protection, RSV variability, duration of protection, flexibility and optimal timing of immunization, benefit for the mother, programmatic implementation, and acceptance of each strategy by key stakeholders. We conclude that, based on current data, immunization of infants with long-acting mAbs might represent the most effective approach for protecting all infants entering their first RSV season.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
KIM, H. W., CANCHOLA, J. G., BRANDT, C. D., PYLES, G., CHANOCK, R. M., JENSEN, K., & PARROTT, R. H. (1969) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a120955 · Cited by 1,981
Evolution of Maternofetal Transport of Immunoglobulins During Human Pregnancy
Malek, A., Sager, R., Kuhn, P., Nicolaides, K. H., & Schneider, H. (1996) · American Journal of Reproductive Immunology · doi:10.1111/j.1600-0897.1996.tb00172.x · Cited by 559
Placental antibody transfer: influence of maternal HIV infection and placental malaria
de Moraes-Pinto, M. I., Verhoeff, F., Chimsuku, L., Milligan, P. J. M., Wesumperuma, L., Broadhead, R. L., Brabin, B. J., Johnson, P. M., & Hart, C. A. (1998) · Archives of Disease in Childhood - Fetal and Neonatal Edition · doi:10.1136/fn.79.3.f202 · Cited by 189
van den Berg, J. P., Westerbeek, E. A. M., Berbers, G. A. M., van Gageldonk, P. G. M., van der Klis, F. R. M., & van Elburg, R. M. (2010) · Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3181dc4f77 · Cited by 112
Okoko, J. B., Wesumperuma, H. L., & Hart, C. A. (2001) · Tropical Medicine & International Health · doi:10.1046/j.1365-3156.2001.00741.x · Cited by 59
Atwell, J. E., Thumar, B., Robinson, L. J., Tobby, R., Yambo, P., Ome-Kaius, M., Siba, P. M., Unger, H. W., Rogerson, S. J., King, C. L., et al. (2016) · Journal of Infectious Diseases · doi:10.1093/infdis/jiv401 · Cited by 48
Cited by
Knowledge and Attitudes Regarding Respiratory Syncytial Virus (RSV) Prevention: A Systematic Review
Gavaruzzi, T., Ceccarelli, A., Nanni, C., Vignali, C., Colonnello, V., Caserotti, M., Riccò, M., & Gori, D. (2025) · Vaccines · doi:10.3390/vaccines13020159 · Cited by 29
Kherfan, T., & Sallam, M. (2023) · Vaccines · doi:10.3390/vaccines11081386 · Cited by 26
Sallam, M., Kherfan, T., Al‐Farajat, A., Nemrawi, L., Atawneh, N., Fram, R., Al‐Tammemi, A. B., Barakat, M., & Fram, K. (2025) · Health Science Reports · doi:10.1002/hsr2.70319 · Cited by 12
Metadata
- Authors
- Esposito, S., Abu Raya, B., Baraldi, E., Flanagan, K., Martinon Torres, F., Tsolia, M., & Zielen, S.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2022-04-28
- Volume
- 13
- Pages
- 880368-880368
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W4285740580
- Cited by
- 149
- References
- 6
- FWCI
- 19.60
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: RSV Prevention in All Infants: Which Is the Most Preferable Strategy? https://app.cochat.ai/papers/10.3389/fimmu.2022.880368
- The paper
- Esposito, S., Abu Raya, B., Baraldi, E., Flanagan, K., Martinon Torres, F., Tsolia, M., & Zielen, S. (2022). RSV Prevention in All Infants: Which Is the Most Preferable Strategy? Frontiers in Immunology. https://doi.org/10.3389/fimmu.2022.880368
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.